0102030405
Apixaban CAS 503612-47-3 Pharmaceutical Raw Material
02
introduce
introduce
Apixaban is a highly selective, reversible oral Factor Xa inhibitor and key antithrombotic pharmaceutical API. It effectively prevents thrombin generation and thrombosis with a favorable safety profile, widely used in preventing and treating thromboembolic diseases.
Our products comply with strict international quality standards, ensuring high purity, stable performance, and reliable supply for pharmaceutical formulation and biomedical research.
02
Physical and chemical properties
Apixaban exhibits critical physicochemical characteristics supporting its pharmaceutical and research applications, as follows:
- Density: 1.42 g/cm³
- Melting Point: 235-238 °C
- Boiling Point: 770.5±60.0 °C
- pKa: 15.01±0.20 (Predicted)
- Solubility: Slightly soluble in DMSO (when heated) and Methanol; insoluble in water
- Density: 1.42 g/cm³
- Melting Point: 235-238 °C
- Boiling Point: 770.5±60.0 °C
- pKa: 15.01±0.20 (Predicted)
- Solubility: Slightly soluble in DMSO (when heated) and Methanol; insoluble in water
1. Lower Bleeding Risk: As a novel oral selective activated Factor X inhibitor, its bleeding-related adverse reactions are significantly lower than those of the traditional anticoagulant Warfarin, with better medication safety.
2. Higher Medication Flexibility: It has a window period of 12-24 hours for the first postoperative dose, which is longer among similar oral anticoagulants. This allows physicians to observe and stabilize patients' conditions before medication administration after surgery.
3. Better Balance between Efficacy and Safety: Compared with Rivaroxaban, another novel oral anticoagulant, both are superior to the standard treatment Enoxaparin in preventing venous thrombosis after orthopedic surgery. Rivaroxaban has slightly better efficacy but carries a higher bleeding risk than Apixaban.
4. More Prominent Efficacy in Orthopedic Indications: Compared with Dabigatran, another novel oral anticoagulant, Apixaban shows more stable efficacy in preventing postoperative venous thrombosis in orthopedics. Dabigatran only demonstrates non-inferior efficacy to the standard regimen in a few studies, with overall performance inferior to Apixaban and Rivaroxaban.
2. Higher Medication Flexibility: It has a window period of 12-24 hours for the first postoperative dose, which is longer among similar oral anticoagulants. This allows physicians to observe and stabilize patients' conditions before medication administration after surgery.
3. Better Balance between Efficacy and Safety: Compared with Rivaroxaban, another novel oral anticoagulant, both are superior to the standard treatment Enoxaparin in preventing venous thrombosis after orthopedic surgery. Rivaroxaban has slightly better efficacy but carries a higher bleeding risk than Apixaban.
4. More Prominent Efficacy in Orthopedic Indications: Compared with Dabigatran, another novel oral anticoagulant, Apixaban shows more stable efficacy in preventing postoperative venous thrombosis in orthopedics. Dabigatran only demonstrates non-inferior efficacy to the standard regimen in a few studies, with overall performance inferior to Apixaban and Rivaroxaban.
1. Thromboembolism Prevention & Treatment: Used for preventing VTE in adult patients undergoing elective hip or knee replacement surgery; preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation; treating deep vein thrombosis (DVT) and pulmonary embolism (PE).
2. Biomedical Research: Applied as a research tool to study Factor Xa-mediated coagulation mechanisms, develop new anticoagulant drugs, and evaluate antithrombotic therapies in preclinical models.
2. Biomedical Research: Applied as a research tool to study Factor Xa-mediated coagulation mechanisms, develop new anticoagulant drugs, and evaluate antithrombotic therapies in preclinical models.
We implement strict full-process quality control, with each batch of Apixaban undergoing rigorous testing of key indicators including purity, solubility, stability, protein binding rate, and biological activity to meet standards.
Equipped with a stable raw material supply chain, we ensure continuous large-scale supply. Our professional technical team provides tailored services, including formulation optimization, application guidance, and post-sales technical support to address customer-specific needs.
Equipped with a stable raw material supply chain, we ensure continuous large-scale supply. Our professional technical team provides tailored services, including formulation optimization, application guidance, and post-sales technical support to address customer-specific needs.
As a leading oral Factor Xa inhibitor, Apixaban has revolutionized thromboembolic disease management with its high selectivity, convenience, and favorable benefit-risk profile. It plays an irreplaceable role in clinical anticoagulation therapy, improving patient outcomes worldwide.
With exceptional product quality, diversified application scenarios, and reliable supply capacity, we are committed to providing high-quality Apixaban API and professional services for global pharmaceutical companies, research institutions, and clinical applications.
Choose our Apixaban to meet your needs in pharmaceutical formulation, thromboembolism research, and clinical treatment. Contact us for more product details and cooperation support.
With exceptional product quality, diversified application scenarios, and reliable supply capacity, we are committed to providing high-quality Apixaban API and professional services for global pharmaceutical companies, research institutions, and clinical applications.
Choose our Apixaban to meet your needs in pharmaceutical formulation, thromboembolism research, and clinical treatment. Contact us for more product details and cooperation support.